In fact, targeting both TAMs and PD-1/PD-L1 is currently highlighted as a combined immunotherapeutic approach.61,62 In addition, considering surgery-induced immunosuppression and TAMs in the wound after surgery, the post-surgery local administration of drug-MPs might ameliorate the immunosuppressive state of the wound, which may favor the control of the tumor relapse. The gene discussed is CD274; the disease is neoplasm.